<DOC>
	<DOCNO>NCT00928018</DOCNO>
	<brief_summary>This trial compare whether use drug call sirolimus graft versus host disease ( GVHD ) prevention decrease chance participant 's lymphoma relapse transplantation , compare use standard GVHD prevention regimen without sirolimus . Since mTOR inhibitor anti-lymphoma activity , use transplantation may lead decrease risk relapse hence good transplantation outcome .</brief_summary>
	<brief_title>Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate Cyclosporine/Mycophenolate Mofetil GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation Patients With Lymphoma</brief_title>
	<detailed_description>- Because one know study option best , participant `` randomize '' one two possible group GVHD prophylaxis : 1 ) sirolimus-containing regimen ( tacrolimus , sirolimus methotrexate ) 2 ) sirolimus-free regimen ( tacrolimus methotrexate cyclosporine mycophenolate mofetil ) . - Participants receive reduce intensity condition regimen . This do prepare body transplantation . This consist combination drug ( either fludarabine busulfan fludarabine , cyclophosphamide low-dose total body irradiation ) . The purpose drug weaken immune system low chance body reject donated stem cell . - Participants also receive GVHD prophylaxis regimen randomize . These drug low chance reject donor cell low chance develop GVHD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients eligible primary indication transplantation among follow : Indolent Bcell nonHodgkin lymphoma ( NHL ) ; Aggressive BCell NHL ; Tcell NHL ; Hodgkin Lymphoma . Patients must one follow combination disease status disease histology time enrollment : 1 ) Patients may transplant part firstline therapy one follow histology : CLL adverse cytogenetics , MCL , Tcell NHL . 2 ) Patients may transplant part treatment relapse refractory disease without prior autologous transplantation one follow histology : Indolent NHL ( include CLL/SLL ) , MCL Tcell NHL . 3 ) Patients may transplant part treatment disease relapse progress autologous transplantation histology list . Patients may also enrol without prior autologous transplantation contraindication autologous transplantation , opinion treat clinician . 4 ) There minimal maximal time interval patient 's last antilymphoma therapy time transplantation . 1872 year age Matched related matched unrelated donor Donor willing donate peripheral blood stem cell meet institutional criterion stem cell donation . The donor must medically eligible donate stem cell accord individual transplant center criterion . Patients Burkitt lymphoma DLBCL cmyc rearrangement Karnofsky performance status le 70 % time registration Prior allogeneic stem cell transplantation ( note prior autologous stem cell transplantation allow ) Uncontrolled infection Serum creatinine 2.0mg/dl great Total bilirubin 2.0mg/dl great ( unless relate hemolysis Gilbert 's syndrome ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 3 time great institutional upper limit normal Left ventricular ejection fraction &lt; 30 % Cholesterol &gt; 500mg/dl triglyceride &gt; 500 mg/dl despite appropriate treatment Seropositivity HIV Pregnancy breastfeeding ( effective contraception must use therapy least 6 month end immunosuppressive agent ) Prior history allergy sirolimus , tacrolimus , cyclosporine , methotrexate MMF Concomitant treatment another investigational drug ( unless clear study chair )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>reduce intensity conditioning</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>RIC transplantation</keyword>
</DOC>